Highlights Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Real-time Estimate Cboe Europe Other stock markets 10:12:20 2024-05-08 EDT			5-day change	1st Jan Change
29.52 ^DKK	+0.43%		-0.17%	-14.88%

04-09	H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	MT
04-09	Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	04-09	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	04-09	CI
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	03-27	MT
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	03-27	CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	03-20	CI
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	03-15	CI
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	02-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW